

# Apple Health PDL Drug Class Motions

# Asthma and COPD Agents

---

- ▶ Anticholinergics
- ▶ Phosphodiesterase 4 Inhibitors
- ▶ Long Acting Muscarinic Agent / Long Acting Beta Agonist Combinations
- ▶ Long Acting Muscarinic Agents
- ▶ Inhaled Corticosteroid Combinations
- ▶ Inhaled Corticosteroids
- ▶ Monoclonal Antibodies

# Asthma and COPD Agents

---

**Motion:** I move that all products in the drug classes listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Buccola**
- ▶ **2<sup>nd</sup>: MacKay**

# Corticosteroids : Glucocorticosteroids

---

- ▶ **Motion:** I move that all products in the Corticosteroids : Glucocorticosteroids class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Davydow**
- ▶ **2<sup>nd</sup>: Corsilles**

# Hematopoietic Agents

---

- ▶ Erythropoiesis-Stimulating Agents (ESAS)
- ▶ Gaucher Disease
- ▶ Granulocyte Colony-Stimulating Factors (G-CSF)
- ▶ Sickle Cell Anemia

# Hematopoietic Agents

---

**Motion:** I move that all products in the drug classes listed on slide 5 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Flynn**
- ▶ **2<sup>nd</sup>: Davydow**

# Immune Modulators : Thalidomide Analogues

---

- ▶ **Motion:** I move that all products in the Immune Modulators : Thalidomide Analogues class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Beste**
- ▶ **2<sup>nd</sup>: Corsilles**

# Oncology Agents

---

- ▶ Alkylating Agents - Oral
- ▶ Antineoplastics Misc - Oral
- ▶ BCL-2 Inhibitors – Oral
- ▶ Histone Deacetylase Inhibitors – Oral
- ▶ Isocitrate Dehydrogenase-1 (IDH1) Inhibitors – Oral
- ▶ Isocitrate Dehydrogenase-2 (IDH2) Inhibitors – Oral
- ▶ Janus Associated Kinase (JAK) Inhibitors – Oral
- ▶ Proteasome Inhibitors – Oral

# Oncology Agents

---

- ▶ XPO1 Inhibitors – Oral
- ▶ Antimetabolites – Oral
- ▶ Phosphatidylinositol 3-Kinase (PI3K) Inhibitors – Oral
- ▶ Imidazotetrazines – Oral
- ▶ Antiestrogens – Oral
- ▶ Estrogens-Antineoplastic – Oral
- ▶ Nitrogen Mustards – Oral
- ▶ Autologous Cellular Immunotherapy (CAR-T)

# Oncology Agents

---

- ▶ Mitotic Inhibitors – Oral
- ▶ Nitrosoureas – Oral
- ▶ Selective Retinoid X Receptor Agonists – Oral
- ▶ Antiadrenals - Oral

# Oncology Agents

---

**Motion:** I move that all products in the drug classes listed on slides 8, 9, and 10 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Davydow**
- ▶ **2<sup>nd</sup>: Buccola**

# Antihyperlipidemics : Adenosine Triphosphate-Citrate Lyase Inhibitors

---

- ▶ **Motion:** I move that all products in the Antihyperlipidemics : Adenosine Triphosphate-Citrate Lyase Inhibitors drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Davydow**
- ▶ **2<sup>nd</sup>: MacKay**

# Bone Density Regulators : Selective Estrogen Receptor Modulators (SERMS)

---

- ▶ **Motion:** I move that all products in the Bone Density Regulators : Selective Estrogen Receptor Modulators (SERMS) drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Corsilles**
- ▶ **2<sup>nd</sup>: Flynn**

# Cardiovascular Agents : Transthyretin Stabilizers

---

- ▶ **Motion:** I move that all products in the Cardiovascular Agents : Transthyretin Stabilizers drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Flynn**
- ▶ **2<sup>nd</sup>: Weiland**

# Endocrine and Metabolic Agents

---

- ▶ Fabry Disease Agents – Oral
- ▶ Homocystinuria Agents – Oral
- ▶ Hyperammonemia Agents – Oral
- ▶ Urea Cycle Disorder Agents – Oral
- ▶ Vasopressin Receptor Antagonists – Oral
- ▶ Hereditary Tyrosinemia Type 1 (HT-1) Agents - Oral

# Endocrine and Metabolic Agents

---

**Motion:** I move that all products in the drug classes listed on slide 15 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Davydow**
- ▶ **2<sup>nd</sup>: Beste**

# Neuromuscular Agents

---

- ▶ Muscular Dystrophy Agents
- ▶ Systemic Lupus Erythematosus Agents
- ▶ Antimyasthenic/Cholinergic Agents

# Neuromuscular Agents

---

**Motion:** I move that all products in the drug classes listed on slide 17 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Corsilles**
- ▶ **2<sup>nd</sup>: MacKay**

# Gastrointestinal Agents : Short Bowel Syndrome

---

- ▶ **Motion:** I move that all products in the Gastrointestinal Agents : Short Bowel Syndrome drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Davydow**
- ▶ **2<sup>nd</sup>: Flynn**

# Hematological Agents – Misc : Aminolevulinate Synthase 1-Directed siRNA

---

- ▶ **Motion:** I move that all products in the Hematological Agents – Misc : Aminolevulinate Synthase 1-Directed siRNA drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Buccola**
- ▶ **2<sup>nd</sup>: Barkett**

# Ophthalmic Agents : Nerve Growth Factors

---

- ▶ **Motion:** I move that all products in the Ophthalmic Agents : Nerve Growth Factors drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Beste**
- ▶ **2<sup>nd</sup>: Davydow**

# Vasopressors : Misc - Oral

---

- ▶ **Motion:** I move that all products in the Vasopressors : Misc – Oral drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: MacKay**
- ▶ **2<sup>nd</sup>: Barkett**